IC
ATXS

Ikarian Capital’s Astria Therapeutics ATXS Stock Holding History

Ikarian Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-140,687
Closed -$1.98M – 120
2024
Q1 		$1.98M Sell
140,687
-234,120
-62% -$2.92M 0.22% 88
2023
Q4 		$2.88M Hold
374,807
– – 0.27% 76
2023
Q3 		$2.8M Sell
374,807
-204,583
-35% -$1.74M 0.34% 68
2023
Q2 		$4.83M Sell
579,390
-290,000
-33% -$3.35M 0.77% 42
2023
Q1 		$11.6M Buy
869,390
+194,214
+29% +$2.63M 2.62% 6
2022
Q4 		$10.1M Sell
675,176
-24,264
-3% -$250K 2.43% 11
2022
Q3 		$6.32M Buy
699,440
+107,317
+18% +$719K 1.26% 26
2022
Q2 		$1.78M Buy
592,123
+499,900
+542% +$2.24M 0.32% 63
2022
Q1 		$619K Buy
92,223
+4,643
+5% +$27.6K 0.08% 119
2021
Q4 		$473K Hold
87,580
– – 0.07% 130
2021
Q3 		$775K Sell
87,580
-1,136
-1% -$10.9K 0.05% 167
2021
Q2 		$1.12M Sell
88,716
-53,450
-38% -$694K 0.09% 154
2021
Q1 		$2.46M Buy
142,166
+33,833
+31% +$611K 0.08% 188
2020
Q4 		$1.39M Buy
+108,333
New +$1.93M 0.06% 168

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital's ATXS Position: Q2 2024 in Review

Ikarian Capital sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 140,687 shares — an estimated $1.98M sold.

Ikarian Capital first reported a position in ATXS in Q4 2020 and held it in 14 quarters. The position peaked at $11.6M in Q1 2023. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Ikarian Capital reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ikarian Capital sold 140,687 Astria Therapeutics shares in Q2 2024, an estimated $1.98M.
  • Ikarian Capital first reported a position in Astria Therapeutics in Q4 2020 and held it in 14 quarters.
  • Ikarian Capital's Astria Therapeutics position peaked at $11.6M in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.